Disclosed herein is a novel and stable amorphous form of tapentadol hydrochloride, process for the preparation, pharmaceutical compositions, and method of treating thereof. Disclosed also herein is a stable amorphous co-precipitates of tapentadol hydrochloride with pharmaceutically acceptable excipients, method for the preparation, pharmaceutical compositions, and method of treating thereof Advantageously, the amorphous co-precipitates of tapentadol hydrochloride of the present invention have improved physiochemical characteristics that assist in the effective bioavailability.
